Latest Period
Q2 2026
Security Snapshot
Vaxcyte, Inc. - Common Stock (PCVX) Institutional Ownership
CUSIP: 92243G108
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
327
Shares (Excl. Options)
166,901,950
Price
$58.13
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- PCVX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 166,901,950
- Total 13F value
- $9,701,761,447
- Portfolio coverage rank
- 0.01%
- Share change
- +2,889,184
- Value change
- +$167,865,165
- Number of holders
- 327
- Shares outstanding
- 149,094,008
- SEC-reported price per share
- $56.00
- Insider filing price
- $56.00
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PCVX - Vaxcyte, Inc. - Common Stock is tracked under CUSIP 92243G108.
- 327 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 336 to 327 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $9,435,711,046 to $9,701,761,447.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 327 institutions filings for Q2 2026.
Security key
92243G108
Latest holder period
Q2 2026
13F holders
327
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
PCVX full holder history
Vaxcyte, Inc. SEC filings
Vaxcyte, Inc. company facts
Vaxcyte, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92243G108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
PCVX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +27% | $1,209,040,462 | +$252,740,288 | 20,798,907 | +26% | FMR LLC | 30 Jun 2026 |
| Janus Henderson Group Ltd. | 12% | +5% | $1,048,686,999 | +$85,131,385 | 18,040,375 | +8.8% | JANUS HENDERSON GROUP Ltd. | 31 Jul 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 8.9% | -10% | $801,181,488 | +$624,169 | 12,974,599 | +0.08% | RA Capital Management, L.P. | 31 Mar 2026 |
| T. Rowe Price Investment Management, Inc. | 8.6% | +37% | $520,196,135 | +$137,268,465 | 11,296,333 | +36% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
| BlackRock, Inc. | 7.6% | $323,263,490 | 9,825,638 | BlackRock, Inc. | 31 Mar 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $421,416,800 | 7,252,053 | Vanguard Capital Management | 31 Mar 2026 |
As of 30 Jun 2026, 327 institutional investors reported holding 166,901,950 shares of Vaxcyte, Inc. - Common Stock (PCVX). This represents 112% of the company’s total 149,094,008 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
90%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 20,852,907 | +26% | 0.05% | $1,212,179,482 |
| Jupiter Topco LLC | 12% | 17,965,847 | 0% | 0.43% | $1,044,355,257 |
| T. Rowe Price Investment Management, Inc. | 8.2% | 12,207,450 | +0.67% | 0.47% | $709,620,000 |
| BlackRock, Inc. | 8.1% | 12,068,129 | +10% | 0.01% | $701,520,339 |
| RA CAPITAL MANAGEMENT, L.P. | 7.7% | 11,474,599 | 0% | 5.8% | $667,018,440 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.7% | 7,001,565 | +25% | 0.07% | $407,000,973 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 6,593,551 | +5% | 0.02% | $383,283,120 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 6,348,679 | +1.3% | 0.01% | $369,048,710 |
| STATE STREET CORP | 3.6% | 5,351,698 | +21% | 0.01% | $311,090,172 |
| Deep Track Capital, LP | 2.9% | 4,300,000 | 0% | 3.7% | $249,959,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 3,459,363 | +8.1% | 0.01% | $201,130,269 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2% | 2,988,999 | +206% | 0.02% | $173,751,000 |
| Kynam Capital Management, LP | 2% | 2,922,335 | 0% | 9.4% | $169,875,334 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.7% | 2,472,428 | -32% | 0.47% | $143,722,240 |
| Caligan Partners LP | 1.5% | 2,188,636 | +6.2% | 6.1% | $127,225,411 |
| Paradigm Biocapital Advisors LP | 1.4% | 2,127,852 | -56% | 2.3% | $123,692,037 |
| Bellevue Group AG | 1.3% | 1,971,935 | +66% | 2.4% | $114,628,582 |
| D. E. Shaw & Co., Inc. | 1.3% | 1,901,872 | -34% | 0.07% | $110,555,819 |
| MAVERICK CAPITAL LTD | 1.1% | 1,613,242 | +17% | 0.85% | $93,777,757 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.98% | 1,464,812 | +4.3% | 0.01% | $85,149,522 |
| Pivotal bioVenture Partners Investment Advisor LLC | 0.96% | 1,425,470 | +3.9% | 27% | $82,862,571 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.93% | 1,380,219 | +0.43% | 1.1% | $80,229,411 |
| GOLDMAN SACHS GROUP INC | 0.91% | 1,350,760 | +5.9% | 0.01% | $78,519,679 |
| NORTHERN TRUST CORP | 0.86% | 1,280,172 | +12% | 0.01% | $74,416,399 |
| NORGES BANK | 0.84% | 1,245,805 | 0.01% | $72,418,645 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q2 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 166,901,950 | $9,701,761,447 | +$167,865,165 | $58.13 | 327 |
| 2026 Q1 | 162,526,130 | $9,435,711,046 | +$770,394,667 | $58.11 | 336 |
| 2025 Q4 | 147,544,842 | $6,807,589,756 | +$262,484,596 | $46.14 | 294 |
| 2025 Q3 | 141,285,706 | $5,088,913,432 | -$216,599,261 | $36.02 | 282 |
| 2025 Q2 | 147,479,114 | $4,794,596,759 | -$48,097,035 | $32.51 | 292 |
| 2025 Q1 | 133,025,604 | $5,021,104,716 | -$42,905,782 | $37.76 | 302 |
| 2024 Q4 | 140,784,610 | $11,525,526,197 | +$183,138,339 | $81.86 | 318 |
| 2024 Q3 | 136,507,040 | $15,592,116,896 | +$1,498,526,683 | $114.27 | 325 |
| 2024 Q2 | 122,578,572 | $9,264,040,265 | +$268,135,107 | $75.51 | 264 |
| 2024 Q1 | 119,065,967 | $8,130,427,051 | +$1,115,777,265 | $68.31 | 249 |
| 2023 Q4 | 103,087,407 | $6,473,142,685 | +$69,029,370 | $62.80 | 223 |
| 2023 Q3 | 101,381,209 | $5,166,522,410 | +$77,032,504 | $50.98 | 202 |
| 2023 Q2 | 99,996,517 | $4,993,540,992 | +$865,860,362 | $49.94 | 194 |
| 2023 Q1 | 84,121,058 | $3,152,798,116 | +$159,886,756 | $37.48 | 186 |
| 2022 Q4 | 81,609,487 | $3,913,093,743 | +$1,140,362,544 | $47.95 | 197 |
| 2022 Q3 | 56,496,728 | $1,356,264,990 | +$122,059,625 | $24.00 | 121 |
| 2022 Q2 | 51,432,581 | $1,119,137,255 | +$31,274,087 | $21.76 | 103 |
| 2022 Q1 | 49,852,918 | $1,203,855,921 | +$69,029,421 | $24.15 | 86 |
| 2021 Q4 | 44,718,114 | $1,063,493,543 | +$32,023,661 | $23.79 | 84 |
| 2021 Q3 | 43,198,231 | $1,095,966,337 | -$195,558 | $25.37 | 77 |
| 2021 Q2 | 43,222,434 | $972,744,067 | -$14,050,462 | $22.51 | 74 |
| 2021 Q1 | 44,022,105 | $869,193,186 | +$26,485,491 | $19.75 | 73 |
| 2020 Q4 | 42,260,768 | $1,118,933,017 | +$58,331,379 | $26.57 | 83 |
| 2020 Q3 | 37,761,937 | $1,857,382,730 | +$103,777,823 | $49.38 | 60 |
| 2020 Q2 | 35,950,832 | $1,126,753,000 | +$1,126,753,000 | $31.61 | 38 |